Hemofiltrate CC Chemokine 1[9-74] Causes Effective Internalization of CCR5 and Is a Potent Inhibitor of R5-Tropic Human Immunodeficiency Virus Type 1 Strains in Primary T Cells and Macrophages

ABSTRACT Proteolytic processing of the abundant plasmatic human CC chemokine 1 (HCC-1) generates a truncated form, HCC-1[9-74], which is a potent agonist of CCR1, CCR3, and CCR5; promotes calcium influx and chemotaxis of T lymphoblasts, monocytes, and eosinophils; and inhibits infection by CCR5-tropic human immunodeficiency virus type 1 (HIV-1) isolates. In the present study we demonstrate that HCC-1[9-74] interacts with the second external loop of CCR5 and inhibits replication of CCR5-tropic HIV-1 strains in both primary T cells and monocyte-derived macrophages. Low concentrations of the chemokine, however, frequently enhanced the replication of CCR5-tropic HIV-1 isolates but not the replication of X4-tropic HIV-1 isolates. Only HCC-1[9-74] and HCC-1[10-74], but not other HCC-1 length variants, displayed potent anti-HIV-1 activities. Fluorescence-activated cell sorter analysis revealed that HCC-1[9-74] caused up to 75% down-regulation of CCR5 cell surface expression, whereas RANTES (regulated on activation, normal T-cell expressed and secreted) achieved a reduction of only about 40%. Studies performed with green fluorescent protein-tagged CCR5 confirmed that both HCC-1[9-74] and RANTES, but not full-length HCC-1, mediated specific internalization of the CCR5 HIV-1 entry cofactor. Our results demonstrate that the interaction with HCC-1[9-74] causes effective intracellular sequestration of CCR5, but they also indicate that the effect of HCC-1[9-74] on viral replication is subject to marked cell donor- and HIV-1 isolate-dependent variations.

[1]  F. Kirchhoff,et al.  Natural Proteolytic Processing of Hemofiltrate Cc Chemokine 1 Generates a Potent Cc Chemokine Receptor (Ccr)1 and Ccr5 Agonist with Anti-HIV Properties , 2000, The Journal of experimental medicine.

[2]  P. Schulz-Knappe,et al.  Posttranslationally processed forms of the human chemokine HCC-1. , 2000, Biochemistry.

[3]  E. Arts,et al.  Variable Sensitivity of CCR5-Tropic Human Immunodeficiency Virus Type 1 Isolates to Inhibition by RANTES Analogs , 2000, Journal of virology.

[4]  M. Foda,et al.  Involvement of both the V2 and V3 Regions of the CCR5-Tropic Human Immunodeficiency Virus Type 1 Envelope in Reduced Sensitivity to Macrophage Inflammatory Protein 1α , 2000, Journal of Virology.

[5]  V. Miller,et al.  Unexpected coreceptor usage of primary human immunodeficiency virus type 1 isolates from viremic patients under highly active antiretroviral therapy. , 2000, The Journal of infectious diseases.

[6]  H. Sticht,et al.  Synthesis and characterization of the human CC chemokine HCC-2. , 1999, The journal of peptide research : official journal of the American Peptide Society.

[7]  J. Albert,et al.  Coreceptor usage and RANTES sensitivity of non-syncytium-inducing HIV-1 isolates obtained from patients with AIDS. , 1999, Journal of human virology.

[8]  H. Schuitemaker,et al.  Adaptation to promiscuous usage of chemokine receptors is not a prerequisite for human immunodeficiency virus type 1 disease progression. , 1999, The Journal of infectious diseases.

[9]  A. Trkola,et al.  The CC-Chemokine RANTES Increases the Attachment of Human Immunodeficiency Virus Type 1 to Target Cells via Glycosaminoglycans and Also Activates a Signal Transduction Pathway That Enhances Viral Infectivity , 1999, Journal of Virology.

[10]  J. Moore,et al.  HIV-1 entry inhibitors: Evading the issue , 1999, Nature Medicine.

[11]  Pascal Poignard,et al.  Highly Potent RANTES Analogues either Prevent CCR5-Using Human Immunodeficiency Virus Type 1 Infection In Vivo or Rapidly Select for CXCR4-Using Variants , 1999, Journal of Virology.

[12]  F. Kirchhoff,et al.  Coreceptor usage of BOB/GPR15 and Bonzo/STRL33 by primary isolates of human immunodeficiency virus type 1. , 1999, The Journal of general virology.

[13]  H. Guy,et al.  Epitope Mapping of CCR5 Reveals Multiple Conformational States and Distinct but Overlapping Structures Involved in Chemokine and Coreceptor Function* , 1999, The Journal of Biological Chemistry.

[14]  R. Doms,et al.  Coreceptor/chemokine receptor expression on human hematopoietic cells: biological implications for human immunodeficiency virus-type 1 infection. , 1999, Blood.

[15]  A. Trkola,et al.  Enhancement of Human Immunodeficiency Virus Type 1 Infection by the CC-Chemokine RANTES Is Independent of the Mechanism of Virus-Cell Fusion , 1999, Journal of Virology.

[16]  J. Farber,et al.  Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. , 1999, Annual review of immunology.

[17]  M. Parmentier,et al.  The inhibitory effect of RANTES on the infection of primary macrophages by R5 human immunodeficiency virus type-1 depends on the macrophage activation state. , 1998, Virology.

[18]  M. Parmentier,et al.  Synthetic full‐length and truncated RANTES inhibit HIV‐1 infection of primary macrophages , 1998, AIDS (London).

[19]  J. Boyd,et al.  Identification of C-C Chemokine Receptor 1 (CCR1) as the Monocyte Hemofiltrate C-C Chemokine (HCC)-1 Receptor , 1998, The Journal of experimental medicine.

[20]  E. De Clercq,et al.  Determinants for Sensitivity of Human Immunodeficiency Virus Coreceptor CXCR4 to the Bicyclam AMD3100 , 1998, Journal of Virology.

[21]  N. Tarasova,et al.  Spontaneous and Ligand-induced Trafficking of CXC-Chemokine Receptor 4* , 1998, The Journal of Biological Chemistry.

[22]  E. Santagostino,et al.  Synthetic full-length and truncated RANTES inhibit HIV-1 infection of primary macrophages. , 1998 .

[23]  M. Wainberg,et al.  Effect of HIV constructs containing protease‐reverse transcriptase fusion proteins on viral replication , 1998, AIDS.

[24]  J. Grivel,et al.  Blockade of CC chemokine receptor 5 (CCR5)-tropic human immunodeficiency virus-1 replication in human lymphoid tissue by CC chemokines. , 1998, The Journal of clinical investigation.

[25]  C. Mackay,et al.  Reduced HIV-1 infectability of CD4+ lymphocytes from exposed-uninfected individuals: association with low expression of CCR5 and high production of beta-chemokines. , 1998, Virology.

[26]  M. Mack,et al.  Aminooxypentane-RANTES Induces CCR5 Internalization but Inhibits Recycling: A Novel Inhibitory Mechanism of HIV Infectivity , 1998, The Journal of experimental medicine.

[27]  Hassan Mohammad Naif,et al.  Cutting Edge: Dichotomous Effects of β-Chemokines on HIV Replication in Monocytes and Monocyte-Derived Macrophages , 1998, The Journal of Immunology.

[28]  A. Trkola,et al.  Genetic Subtype-Independent Inhibition of Human Immunodeficiency Virus Type 1 Replication by CC and CXC Chemokines , 1998, Journal of Virology.

[29]  J. Hoxie,et al.  Phorbol Esters and SDF-1 Induce Rapid Endocytosis and Down Modulation of the Chemokine Receptor CXCR4 , 1997, The Journal of cell biology.

[30]  C. Mackay,et al.  Interaction of Chemokine Receptor CCR5 with its Ligands: Multiple Domains for HIV-1 gp120 Binding and a Single Domain for Chemokine Binding , 1997, The Journal of experimental medicine.

[31]  R. Doms,et al.  Unwelcomed guests with master keys: how HIV uses chemokine receptors for cellular entry. , 1997, Virology.

[32]  A. Trkola,et al.  Co-receptors for HIV-1 entry. , 1997, Current opinion in immunology.

[33]  Jean Salamero,et al.  HIV Coreceptor Downregulation as Antiviral Principle: SDF-1α–dependent Internalization of the Chemokine Receptor CXCR4 Contributes to Inhibition of HIV Replication , 1997, The Journal of experimental medicine.

[34]  B. Cullen,et al.  HIV‐1‐induced cell fusion is mediated by multiple regions within both the viral envelope and the CCR‐5 co‐receptor , 1997, The EMBO journal.

[35]  T. Schwartz,et al.  Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist. , 1997, Science.

[36]  A. Garzino-Demo,et al.  The V3 domain of the HIV–1 gp120 envelope glycoprotein is critical for chemokine–mediated blockade of infection , 1996, Nature Medicine.

[37]  Marc Parmentier,et al.  Regions in β-Chemokine Receptors CCR5 and CCR2b That Determine HIV-1 Cofactor Specificity , 1996, Cell.

[38]  M. Baggiolini,et al.  HIV blocked by chemokine antagonist , 1996, Nature.

[39]  M. Bukrinsky,et al.  Chemokines and HIV replication , 1996, Nature.

[40]  Steven M. Wolinsky,et al.  Relative resistance to HIV–1 infection of CD4 lymphocytes from persons who remain uninfected despite multiple high–risk sexual exposures , 1996, Nature Medicine.

[41]  M. Raida,et al.  HCC-1, a novel chemokine from human plasma , 1996, The Journal of experimental medicine.

[42]  S. Arya,et al.  Identification of RANTES, MIP-1α, and MIP-1β as the Major HIV-Suppressive Factors Produced by CD8+ T Cells , 1995, Science.

[43]  M. Reitz,et al.  Growth of macrophage-tropic and primary human immunodeficiency virus type 1 (HIV-1) isolates in a unique CD4+ T-cell clone (PM1): failure to downregulate CD4 and to interfere with cell-line-tropic HIV-1 , 1995, Journal of virology.

[44]  Mauro Vaccarezza,et al.  Role of Lymphoid Organs in the Pathogenesis of Human Immunodeficiency Virus (HIV) Infection , 1994, Immunological reviews.

[45]  P. Sharp,et al.  A molecular clone of HIV-1 tropic and cytopathic for human and chimpanzee lymphocytes. , 1993, Virology.

[46]  J. Kappes,et al.  Molecular characterization of human immunodeficiency virus type 1 cloned directly from uncultured human brain tissue: identification of replication-competent and -defective viral genomes , 1991, Journal of virology.

[47]  A. Cann,et al.  Human immunodeficiency virus type 1 T-cell tropism is determined by events prior to provirus formation , 1990, Journal of virology.

[48]  H. Vinters,et al.  Dual infection of the central nervous system by AIDS viruses with distinct cellular tropisms. , 1987, Science.